News Wire
UNLOCKING THE RHYTHM: CIPLA LAUNCHES THE TUFFIES SONG AS PART OF THE NEXT WAVE OF THE CAMPAIGN WITH SHANKAR MAHADEVAN
- Spreading the Tuffies mission, of dispelling misconceptions, and promoting proactive respiratory health management, the mighty melody has been composed and sung by Shankar Mahadevan
- Launch of the second Tuffies comic book co-created with paediatricians from India
- ‘Tuffies ki School Yatra’, a multi-city school contact program launches, set to cover 1000+ schools across six cities
MUMBAI, India, Jan. 11, 2024 /PRNewswire/ — Empowering kids living with chronic respiratory conditions like asthma through the magic of music, Cipla forays into the next phase of its Tuffies campaign with a new song. The mighty melody has been sung and composed by Shankar Mahadevan and conceptualised with creative agency ^ a t o m network. With the aim of spreading the Tuffies mission nationwide, the new song will be part of the company’s strengthened efforts to promote paediatric respiratory care awareness through both online and offline channels. The Tuffies song is now available across Cipla’s social channels.
Listen to the Tuffies ‘Dhan-ta-daa’ song: https://youtu.be/L54mS5grSY0?feature=shared
Speaking on the launch of the new song, Mr. Achin Gupta, CEO – One India Business at Cipla Ltd. said, “Music has always been an incredible medium of expression and at Cipla we have tremendous belief in its ability to inspire, motivate and unite. We’re excited to launch the ‘Dhan-ta-daa’ song specifically created for little Tuffies across the country and we’re especially excited to have collaborated with the talented Shankar Mahadevan to help us bring the spirit of ‘Tuffies’ alive.”
Singer and composer Mr. Shankar Mahadevan said, “Music is a powerful tool for storytelling and I’m so happy to have been presented with the opportunity to be part of such a special project that brings attention to a serious and relevant cause. Learning about the impact of a disease like asthma on little ones across the country was an eye-opener and Cipla’s commitment to these little ‘Tuffies’ is commendable. Melodious and catchy, our hope is that this song resonates with children, enabling them to take charge of their own health and give them the courage to achieve their full potential.”
The song launch will be coupled with new initiatives that includes a second comic book titled, ‘Mystery of the Lost Kitty’, which for the first time has been co-created with Indian paediatricians. Furthermore, recognizing the crucial role of schools in promoting health education, the company has rolled out the ‘Tuffies ki School Yatra’ to 1000+ schools across the country. Through this hands-on approach the company hopes to empower students and staff with the knowledge to navigate respiratory conditions, dispel misconceptions, and promote proactive respiratory health management. In addition to asthma screening opportunities, the yatra includes fun activities like blow painting for kids, engaging group sessions with healthcare professionals for staff members, and opportunities for parents to feature their child in the next Tuffies comic book.
Link to read second comic book, ‘Mystery of the Lost Kitty’: https://www.breathefree.com/tuffies/read-comics/
Speaking on the new comic book and the ‘Tuffies Ki School Yatra’, Mr. Achin Gupta, CEO – One India Business at Cipla Ltd., “Addressing India’s young population, where 70-82% of those suffering from wheezing or severe asthma remain undiagnosed[1], Tuffies aims to educate and entertain children in a relatable language. Exemplifying the power of tailored creative storytelling in effectively engaging audiences, the slew of offline and online activities will only further bolster these ambitions and aid our mission of raising awareness about paediatric respiratory care.”
Led by the delightful, animated characters Vicky, Mini, Gullu and Mr. Puffy – Tuffies hopes to inspire children with respiratory conditions, like asthma, to take charge of their health through dynamic storytelling and engagement. It also assists parents and caregivers in distinguishing between accurate information and misconceptions about these conditions.
For more information on Tuffies visit: www.breathefree.com/tuffies
Disclaimer: This information is only for general awareness and is neither intended nor expected to promote, use, or endorse any product or encourage use of medicines or treatment in any way nor implied to be a substitute for professional medical advice nor for diagnosis or treatment/cure of any medical condition. The views expressed are independent opinion based on studies from validated qualified sources. Your discretion must be exercised before using the information for consulting doctor. Please consult your doctor/Registered Medical Practitioner before starting any treatment/medicine/ inhaler. This is being used only as a reference to create awareness and is NOT an advertisement.
About Cipla:
Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 86 markets. Cipla is the 3rd largest in pharma in India (IQVIA MAT March’23), 3rd largest in the pharma private market in South Africa (IQVIA MAT March’23), and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.
[1] Singh, Sheetu et al. “Prevalence, time trends and treatment practices of asthma in India: The Global Asthma Network study.” ERJ open research vol. 8,2 00528-2021. 30 May. 2022, doi:10.1183/23120541.00528-2021
Photo: https://oyefilmy.com/wp-content/uploads/2024/01/unlocking-the-rhythm-cipla-launches-the-tuffies-song-as-part-of-the-next-wave-of-the-campaign-with-shankar-mahadevan-1.jpg
Logo: https://oyefilmy.com/wp-content/uploads/2024/01/unlocking-the-rhythm-cipla-launches-the-tuffies-song-as-part-of-the-next-wave-of-the-campaign-with-shankar-mahadevan-2.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/unlocking-the-rhythm-cipla-launches-the-tuffies-song-as-part-of-the-next-wave-of-the-campaign-with-shankar-mahadevan-302030873.html
News Wire
Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network
MUMBAI, India, March 11, 2026 /PRNewswire/ — Reliance Digital announces the offline retail availability of iQOO, the high-performance smartphone brand built for today’s youth and tech-forward consumers. Following strong traction in online channels, iQOO is now extending its presence into physical retail, allowing customers to experience and purchase its devices first-hand at Reliance Digital stores across India.
Known for pushing the boundaries of speed, and power, the iQOO 15R is powered by the Snapdragon 8 Gen 5, delivering exceptional speed, responsiveness, and sustained performance throughout the day. It packs iQOO’s biggest battery yet in an ultra-slim 7.90mm design, making it India’s slimmest smartphone with a 7600 mAh battery.
The device features a 6.5K IceCore VC Cooling Chamber for stable performance and runs on OriginOS 6.0 based on Android 16 out of the box, supported by 4 years of software updates and 6 years of security updates. It is also equipped with a Sony LYT-700V OIS camera, a 1.5K 144Hz AMOLED EyeCare display, and IP68 & IP69 dust and water resistance, making it a dependable daily partner for professionals on the go.
The brand’s offline expansion marks an important step in deepening consumer engagement by offering hands-on access to its devices, enabling customers to explore iQOO’s powerful performance, advanced display technology, and flagship-grade camera capabilities in a real-world retail environment.
The availability of iQOO at Reliance Digital brings together two brands driven by innovation and consumer experience. While iQOO continues to build its reputation as a performance-led smartphone brand, Reliance Digital strengthens its portfolio by offering customers access to cutting-edge technology brands through its extensive nationwide retail network.
Through engaging in-store experiences, knowledgeable staff, and immersive product demonstrations, Reliance Digital aims to help consumers better understand iQOO’s performance-first DNA. This move further reinforces Reliance Digital’s commitment to staying ahead of evolving consumer preferences and serving as a preferred destination for discovering new-age technology.
With this expansion, Reliance Digital continues to play a key role in shaping India’s consumer electronics landscape by bringing future-ready brands closer to customers, while enabling smartphone brands like iQOO to build stronger connections with a growing, performance-driven audience.
The all new iQOO 15R is now available at Reliance Digital stores nationwide.
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/reliance-digital-introduces-high-performance-iqoo-15r-to-its-nationwide-store-network-302711079.html
News Wire
Kotak Alts announces winner of the inaugural Katalyst Awards
Ms Himani Choudhary named Katalyst for the year – India’s Best Financial Content Creator; wins Rs. 25 Lakhs
MUMBAI, India, March 10, 2026 /PRNewswire/ — Kotak Katalyst Awards, a national initiative instituted to recognise excellence and responsibility in financial content creation has announced the winner of its first Katalyst edition. Kotak Alternate Asset Managers Limited (“Kotak Alts”) today announced Himani Choudhary as the winner. The winner was awarded a prize of INR 25 Lakhs, positioning Katalyst among the most meaningful recognitions for financial content creators in India.
Srini Sriniwasan, Managing Director, Kotak Alts, said, “The Kotak Alts Katalyst Awards were instituted to recognize content creators who are contributing meaningfully to financial literacy in India. As investor participation deepens, audiences are seeking clarity, context, and credibility. The response from creators was overwhelming and points to the new generation of financial educators. As the inaugural winner Ms. Himani Chaudhary, exemplifies the standard of financial communication that Katalyst seeks to encourage.”
The first edition of the Kotak Alts Katalyst Awards received over six hundred entries from across 19 states and in 8 languages, reflecting the growing role of digital creators in shaping financial awareness. Conceived in response to increasing clutter and misinformation in the financial ecosystem, Katalyst is designed to recognize creators who place accuracy, transparency, and investor interest at the core of their work.
The winning content, ‘Personal Finance & Major Finance Updates’ by Himani Choudhary, was recognised for its clarity, originality, and credibility. The jury noted the content’s ability to explain complex financial concepts in a clear and measured manner, supported by strong research and a consistent focus on investor education over virality.
To ensure a robust and transparent evaluation process, the awards framework was designed and audited by EY. The top thirty entries were assessed by an academic jury.
The top 10 finalists were subsequently evaluated by a grand jury comprising Kunal Shah, Founder and CEO of CRED; Radhika Gupta, Managing Director and CEO of Edelweiss Mutual Fund; and Alpesh Shah, Managing Director and Senior Partner at Boston Consulting Group, and chaired by Ananth Narayan, former Whole–Time Member of SEBI with extensive capital markets and regulatory experience.
The Katalyst Awards recognise financial content creators who priorities financial literacy, substance, and long–term investor interest. Through this initiative, Kotak Alts aims to encourage responsible financial communication and support the development of informed and confident investors across India.
About Kotak Alternate Asset Managers Ltd: Kotak Alternate Asset Managers Limited (‘Kotak Alts’), a part of Kotak Mahindra Group (‘Kotak’), focuses on Alternate Asset Management and Investment Advisory businesses. Kotak Alts was set up in early 2005 and has raised, managed, and advised over USD 22 billion across different asset classes, including Private Equity, Real Estate, Infrastructure, Special Situations, Private Credit, and Investment Advisory. The asset management business and investment advisory vertical are managed by independent specialist teams. For more information, visit https://www.kotakalternateasset.com/
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/kotak-alts-announces-winner-of-the-inaugural-katalyst-awards-302709187.html
News Wire
Paperpal for Life Sciences Establishes HIPAA Readiness, Strengthening Enterprise Adoption of AI in Regulated Medical and Scientific Writing Workflows
MUMBAI, India, March 10, 2026 /PRNewswire/ — Paperpal for Life Sciences, an enterprise-grade Artificial Intelligence (AI) platform by Cactus Communications, purpose-built for Medical Affairs and Life Sciences organizations, announced the completion of an assessment evaluating its operational and technical safeguards to support Health Insurance Portability and Accountability Act (HIPAA) requirements. This milestone reinforces Paperpal’s commitment to meeting the rigorous standards of security, data protection, and regulatory readiness required for regulated scientific workflows.
Growing AI use in medical affairs writing and publication workflows is intensifying scrutiny on data privacy, governance, and regulatory accountability. To support these evolving needs, Paperpal for Life Sciences has undertaken an assessment of its systems and processes to evaluate readiness to support HIPAA compliance, where applicable, and now proudly offers the option to execute a Business Associate Agreement (BAA) for Protected Health Information (PHI) and Personally Identifiable Information (PII). This offering gives customers the confidence that PHI or PII, if received, is handled securely and responsibly, in line with regulatory expectations and enterprise risk management practices.
Paperpal for Life Sciences provides AI writing, literature search, source-grounded summarization with citation support, and critical publication checks, powering medical affairs content creation under stringent data privacy and governance controls. The platform accelerates research-to-publication timelines by upto 25%, supporting faster dissemination of clinical evidence and earlier commercialization of new drugs and therapies.
Nishchay Shah, Group CTO and EVP, Products and AI at Cactus Communications, said, “As AI becomes foundational to regulated scientific and medical workflows, compliance and trust are no longer optional. Paperpal for Life Sciences’ HIPAA readiness measures reflect our secure-by-design approach to AI, strong data governance framework, and alignment with real-world enterprise and regulatory requirements. This milestone enables organizations to adopt AI at scale with confidence that their data, processes, and compliance obligations are protected .”
Elvira Dsouza, President, Cactus Life Sciences, added, “Medical Affairs and Life Sciences teams operate in highly regulated environments where scientific rigor, data privacy, and compliance are non-negotiable. HIPAA readiness positions Paperpal for Life Sciences as a trusted AI partner, one that enables organizations to accelerate evidence generation and scientific communication without compromising regulatory integrity .”
With this announcement, Paperpal for Life Sciences reinforces its position as a purpose-built, enterprise-ready AI platform for medical affairs content generation that supports innovation while meeting the highest standards of privacy, ethics, and regulatory compliance.
Media Contact:
Nidhi Amin
nidhi.amin@cactusglobal.com
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/paperpal-for-life-sciences-establishes-hipaa-readiness-strengthening-enterprise-adoption-of-ai-in-regulated-medical-and-scientific-writing-workflows-302708082.html
India Emerging as Stable Investment Anchor in Turbulent Global Economy, Say Investors at IGF Mumbai 2026
Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network
Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network
-
Buzz2 months agoGLOBAL PAY – A New Era in Oman’s Digital Payments Solution
-
Buzz1 month agoCASA BACARDÍ unveils its first Tropical Edition in Goa, celebrating music, culture and collective expression
-
Buzz2 months agoOTM 2026 Set to Bring the Global Travel Industry to Mumbai as India’s Outbound Market Accelerates
-
Buzz1 month agoNew report from Standard Chartered highlights optimistic corporate outlook on India’s energy transition
-
Buzz3 weeks ago70% of Indian Firms Say Cross-Border Trade Has Become Harder to Navigate
-
Buzz1 month ago‘Made in India – The story of Desh Bandhu Gupta, Lupin and Indian Pharma’ Book Launched in Mumbai
-
News Wire1 month agoShriram Life Insurance launches Zaroorat Jaisi, Policy Vaisi: A Fully AI-Created Ad Film Campaign featuring Rahul Dravid
-
News Wire3 weeks agosuper.money Emerges as Market Disruptor, Named India’s Fastest Growing Payments App
You must be logged in to post a comment Login